Article references (48 references )

  1. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998 Oct 16;47(RR-19):1-39.. PubMed | Google Scholar

  2. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010 Feb;14(1):1-21, vii. PubMed | Google Scholar

  3. Williams R. Global challenges in liver disease. Hepatology. 2006;44(3):521-6. PubMed | Google Scholar

  4. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):41-6. PubMed | Google Scholar

  5. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis. 2002 May;2(5):293-302. PubMed | Google Scholar

  6. WHO. Weekly Epidemiological Record. 1999 22.08.2012; 49(10): Available from:

  7. Pybus OG, Drummond AJ, Nakano T, Robertson BH, Rambaut A. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol. 2003 Mar;20(3):381-7. PubMed | Google Scholar

  8. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000 Mar 11;355(9207):887-91. PubMed | Google Scholar

  9. Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004 Jan;44(1):20-9. PubMed | Google Scholar

  10. Maheshwari A, Thuluvath PJ. Management of acute hepatitis C. Clin Liver Dis. 2010 Feb;14(1):169-76; x. PubMed | Google Scholar

  11. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008 Oct;122(10):990-1003. PubMed | Google Scholar

  12. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission?. Hepatology. 2010 Oct;52(4):1497-505. PubMed | Google Scholar

  13. Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis. 2010 Nov;14(11):e928-40. PubMed | Google Scholar

  14. Lam NC, Gotsch PB, Langan RC. Caring for pregnant women and newborns with hepatitis B or C. Am Fam Physician. 2010 Nov 15;82(10):1225-9. PubMed | Google Scholar

  15. Owusu-Ofori S, Temple J, Sarkodie F, Anokwa M, Candotti D, Allain J-P. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion. 2005;45(2):133-40. PubMed | Google Scholar

  16. Jeannel D, Fretz C, Traore Y et al. Evidence for high genetic diversity and longterm endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. J Med Virol 1998.;55(2):92?7. PubMed | Google Scholar

  17. Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature - HENCORE Group - (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol. 2000 Jun;12(6):667-78. PubMed | Google Scholar

  18. Simonsen L, Kane A, Lloyd J et al. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ. 1999;77((10)):789?800. PubMed | Google Scholar

  19. Gibb DM, Goodall RL, Dunn DT et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet. 2000;356(9233):904-7. PubMed | Google Scholar

  20. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007 May 7;13(17):2436-41. PubMed | Google Scholar

  21. Pearlman BL. Hepatitis C Virus Infection in African Americans. Clinical Infectious Diseases. 2006 January 1, 2006;42(1):82-91. PubMed | Google Scholar

  22. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001 Jul 5;345(1):41-52.. PubMed | Google Scholar

  23. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med. 2002 Dec 17;137(12):961-4. PubMed | Google Scholar

  24. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82. PubMed | Google Scholar

  25. Friedrich-Rust M, Zeuzem S, Sarrazin C. Current therapy for hepatitis C. Int J Colorectal Dis. 2007 Apr;22(4):341-9. PubMed | Google Scholar

  26. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2;140(5):346-55. PubMed | Google Scholar

  27. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65. PubMed | Google Scholar

  28. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus- related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999;29:1311?6. PubMed | Google Scholar

  29. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(S1):S35-S46. PubMed | Google Scholar

  30. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000 Feb 15;132(4):296-305. PubMed | Google Scholar

  31. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology. 2002 May;122(6):1554-68. PubMed | Google Scholar

  32. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C - Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19;339(21):1485-92. PubMed | Google Scholar

  33. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C - The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997 Mar 22;349(9055):825-32. PubMed | Google Scholar

  34. Kim AI, Saab S. Treatment of hepatitis C. The American journal of medicine. 2005;118(8):808-15. PubMed | Google Scholar

  35. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49(4):1335-74. PubMed | Google Scholar

  36. Sandeep M, Dhawan VK. Hepatitis C Treatment & Management. In: Katz J, editor. Medscape reference 2012. Google Scholar

  37. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 1997 Sep;26(3 Suppl 1):2S-10S. Google Scholar

  38. McHutchison JG, Shad JA, Gordon SC, Morgan TR, Ling MH, Garaud JJ, et al. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat. 2001 Nov;8(6):414-20. PubMed | Google Scholar

  39. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus - International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998 Oct 31;352(9138):1426-32. PubMed | Google Scholar

  40. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol. 2002 Oct;37(4):500-6. PubMed | Google Scholar

  41. Richter SS. Laboratory assays for diagnosis and management of hepatitis C virus infection. J Clin Microbiol. 2002 Dec;40(12):4407-12. PubMed | Google Scholar

  42. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement - European Association for the Study of the Liver. J Hepatol. 1999 May;30(5):956-61. PubMed | Google Scholar

  43. Pawlotsky J-M, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of Hepatitis C Virus RNA Quantification. Hepatology. 2000;32(3):654-9. PubMed | Google Scholar

  44. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection. New England Journal of Medicine. 2011;364(13):1195-206. PubMed | Google Scholar

  45. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011 Jun 23;364(25):2405-16. PubMed | Google Scholar

  46. Miro JM, Laguno M, Moreno A, Rimola A. Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)?. J Hepatol. 2006;44(1 Suppl):S140-5. PubMed | Google Scholar

  47. Linney D. Costs and Coverage of New Hepatitis C Drugs. Hemaware Bleeding Disorders Magazine. 2011. Google Scholar

  48. Daw MA, Dau AA. Hepatitis C virus in Arab world: a state of concern. Scientific World Journal. 2012;2012:719494. PubMed | Google Scholar